Mineralys Therapeutics price target raised to $42 from $30 at H.C. Wainwright
H.C. Wainwright analyst Matthew Caufield raised the firm’s price target on Mineralys Therapeutics (MLYS) to $42 from $30 and keeps a Buy rating ...